Could one shot stop RSV and hMPV? GSK begins human trials
NCT ID NCT07628049
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests an experimental vaccine from GSK that targets two respiratory viruses: RSV and hMPV. About 1,800 adults aged 18-80 will receive different doses to check safety and immune response. The goal is to see if a single shot can protect against both viruses, which can cause serious lung infections in older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSV/hMPV combination vaccine
- What this could lead to
- If successful, this could lead to a single vaccine protecting against two common respiratory viruses, reducing severe illness in older adults.
- What could go wrong
- This is an early phase 1/2 trial focused on safety and immune response, not yet proven to prevent infection. The vaccine may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS+METAPNEUMOVIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGLenexa, Kansas, 66219, United States
-
GSK Investigational Site
RECRUITINGSeattle, Washington, 98104, United States
-
GSK Investigational Site
RECRUITINGBotany, New South Wales, 2019, Australia
-
GSK Investigational Site
RECRUITINGCamberwell, Victoria, 3124, Australia